Liraglutide

Nature Reviews Drug Discovery

Volumn 9, Issue 4, 2010, Pages 267-268

  Drucker, Daniel J ^a   Dritselis, Argyris ^b   Kirkpatrick, Peter ^c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MS Health   (United Kingdom)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; UNCLASSIFIED DRUG; VISTOZA;

DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY; UNITED STATES;

ADULT; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77950501202     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3148     Document Type: Short Survey

References (17)

1. Nathan, D. M. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193-203 (2009).
2. Lovshin, J. A. & Drucker, D. J. Incretin-based therapies for type 2 diabetes mellitus. Nature Rev. Endocrinol. 5, 262-269 (2009).
3. Knudsen, L. B. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664-1669 (2000).
4. US Food and Drug Administration. FDA labelling information \ Victoza (liraglutide). FDA website [online], http://www.accessdata.fda.gov/drugsatfda- docs/ label/2010/022341lbl.pdf (2010).
5. Garber, A. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473-481 (2009).
6. Nauck, M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32, 84-90 (2009).
7. Marre M. et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet. Med. 26, 268-278 (2009).
8. Russell-Jones, D. et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52, 2046-2055 (2009).
9. Zinman, B. et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32, 1224-1230 (2009).
10. Buse, J. B. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39-47 (2009).
11. Drucker, D. J. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372, 1240-1250 (2008).
12. Drucker, D. J. et al. Incretin-based therapies for the treatment of type 2 diabetes; evaluation of the risks and benefits. Diabetes Care 33, 428-433 (2010).
13. Bunck, M. C. et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32, 762-768 (2009).
14. Knudsen, L. B. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 4 Mar 2010 (doi:10.1210/en.2009-1272)
15. Ban, K. et al. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J. Am. Soc. Hyperten. 3, 245-259 (2009).
16. IMS MIDAS (IMS Health, 2009).
17. Vosser, R. Hauber, A. & Gordon, J. D. Europe Equity Research Report (J. P. Morgan, 5 Feb 2010).